NHS Waited Decade for Celebrity to Fund Screening Test

England's National Health Service announced in 2024 that all newborn babies will now be screened for Spinal Muscular Atrophy, a genetic condition that kills or severely paralyzes children before age five.

The test is a heel prick. It costs pennies.

The beneficiary question cuts straight through the delay. Who wanted SMA screening added to the routine test? Families with the disease, patient advocacy groups, and geneticists. The evidence was there.

The answer sits in a formula that NHS budget committees use to decide what to fund. They calculate cost per quality-adjusted life year, abbreviated as QALY. For SMA screening, the number landed somewhere above £50,000 per QALY gained. Below £20,000 per QALY, you fund it. Above £30,000, you can defend exclusion without triggering outrage.

Not funding a screening test for a deadly genetic disease is defensible as fiscal responsibility. Not funding one while a major celebrity is watching is defensible as cruelty.

Not funding a screening test for a deadly genetic disease is defensible as fiscal responsibility. Not funding one while a major celebrity is watching is defensible as cruelty. The NHS moved because the incentive structure shifted, not because the evidence changed. This is how institutional resistance to good ideas actually works. Not through conspiracy, but through cost-benefit analysis that remains invisible until the cost of non-compliance exceeds the cost of compliance.

You see this in your own work whenever you watch a mediocre solution persist until someone with enough authority or visibility decides it's worth disrupting. The solution was always available. The problem was always real. What changed was whether someone had enough leverage to make the status quo uncomfortable.